Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Two prediction markets, Kalshi and Polymarket, are now offering bets on clinical trial outcomes, according to NPR News. Researchers warn the practice could incentivize insider trading and interfere with drug development, while the markets say they provide valuable information to patients.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton